Recent advances in the treatment of Parkinsonism with drugs.
D000547:Amantadine / Q000627:therapeutic use*; D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001812:Blood-Brain Barrier; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002490:Central Nervous System / Q000187:drug effects / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004347:Drug Interactions; D004361:Drug Tolerance; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D001523:Mental Disorders / Q000139:chemically induced; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D051381:Rats; D013997:Time Factors; D014839:Vomiting
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D004298:Dopamine